Peptide News Digest

#Lanifibranor

2 stories

Clinical Trials · View digest

Inventiva Completes Last Patient Last Visit in Phase 3 NATiV3 Trial of Lanifibranor in MASH; Topline Data Expected Q4 2026 With NDA H1 2027

Inventiva SA (NASDAQ: IVA) announced Wednesday September 2, 2026 completion of the last patient's final 72-week visit in the Phase 3 NATiV3 study of lanifibranor (a pan-PPAR α/δ/γ agonist) in adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis. Enrollment: 1,009 patients in the main cohort plus an additional 410 patients in the exploratory cohort. NATiV3 assesses lanifibranor on histological endpoints including MASH resolution and improvement of fibrosis of at least one stage after 72 weeks of treatment. Inventiva expects to report topline data in Q4 2026 with NDA filing planned for H1 2027. Lanifibranor differentiates from the standard-of-care Madrigal Rezdiffra (resmetirom, THR-β agonist, approved March 2024) plus the emerging Boehringer Ingelheim survodutide, Novo Nordisk semaglutide MASH, and Akero Therapeutics efruxifermin (FGF21) programs by engaging three complementary PPAR isoforms in parallel to address steatosis, inflammation, and fibrosis.

Research · View digest

Nature: Unimolecular GLP-1R/GIPR/PPARα/γ/δ Quintuple Agonist Conjugate Reverses Obesity and Insulin Resistance in Mice

A Nature paper from Liskiewicz, DiMarchi, Tschöp, Müller and colleagues introduces a unimolecular peptide-drug conjugate that combines a GLP-1R/GIPR co-agonist peptide with the pan-PPAR (α/γ/δ) agonist lanifibranor via a pH-sensitive linker. After receptor-mediated internalization, the linker cleaves and lanifibranor escapes to the nucleus to activate PPARs while the peptide moiety drives GLP-1R/GIPR signaling at the membrane. In obese, diabetic mice the conjugate produced greater weight loss and insulin sensitization than equimolar dosing of the unconjugated peptide and lanifibranor, without the typical PPAR-related cardiac and weight-gain safety signals.